Valeant Pharmaceuticals CEO Michael Pearson just got back from a two-month sick leave, and immediately faced a fresh round of criticism and doubts about the company’s financial disclosures and business practices.
WSJ.com: Management, Wall Street Journal: Business: Management
Tue, 03/01/2016 - 6:38pm
Valeant Pharmaceuticals CEO Michael Pearson just got back from a two-month sick leave, and immediately faced a fresh round of criticism and doubts about the company’s financial disclosures and business practices.